P164 Utility of LCI2.5 as an outcome measure for people with cystic fibrosis of all ages – Experience from a pilot feasibility trial spanning adult and paediatric care

Miller, Debbie, Kilarski, E., Taylor, Emily, Cunningham, Steve, Lewis, Steff, Neilson, Aileen, Bowen, Donna, Lacey, Ellen, Abkir, Mary, Saunders, C., Vogiatzis, Ioannis, Allen, Lorna, Soilemezi, Dia, Saynor, Zoe and Urquhart, Don S. (2024) P164 Utility of LCI2.5 as an outcome measure for people with cystic fibrosis of all ages – Experience from a pilot feasibility trial spanning adult and paediatric care. Journal of Cystic Fibrosis, 23, S105. (doi:10.1016/S1569-1993(24)00426-0).

Abstract

Lung clearance index (LCI2.5), measured by nitrogen-multiple breath washout (N2-MBW), is a measure of ventilation inhomogeneity and a promising endpoint for clinical trials in cystic fibrosis (CF). The utility of LCI2.5 in adult lung disease has been questioned, due to long test times. LCI2.5 was included as a key safety outcome in the ‘Exercise as an Airway Clearance Technique in CF (ExACT-CF)’ study – a randomised, pilot feasibility trial comparing daily ExACT with usual care (chest physiotherapy). We report utility of LCI2.5 as an outcome measure in this 28-day trial which spanned adult and paediatric age groups.

This record has no associated files available for download.

Contributors

Author: Zoe Saynor

Download statistics